Literature DB >> 11324777

Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.

C Salvarani1, G G Hunder.   

Abstract

OBJECTIVE: To determine the frequency of a low erythrocyte sedimentation rate (ESR) in patients with giant cell arteritis (GCA) and evaluate their clinical features in a defined population.
METHODS: A total of 167 patients with GCA were identified in the population of Olmsted County, Minnesota, between the years 1950 and 1998 using methods described in previous studies. All fulfilled American College of Rheumatology criteria for GCA.
RESULTS: In 9 of the 167 patients the ESR was less than 40 mm/hour (Westergren method) at diagnosis. These patients had less frequent systemic symptoms and visual symptoms than the others. No patient with low ESR developed blindness. Other manifestations were similar in those with low and those with high ESR. The response of symptoms to prednisone treatment was within 1 week, and after a median of 25 days of therapy the median ESR dropped from 19 mm/hour to 3 mm/hour. The median duration of glucocorticoid therapy in the 9 patients was 21.5 months and median followup after diagnosis was 12.5 years. Over a long period of observation (median 44 years) in the 9 patients with low ESR, 9 inflammatory events other than GCA were observed in 7 patients. The ESR was normal in 7 of these 9 other events.
CONCLUSION: A low ESR in active GCA is not a rare occurrence. Causes may include localized arteritis in some patients and an inability to mount an acute phase serologic response in others.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11324777     DOI: 10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

Review 1.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

3.  Vasculitis syndromes: Not losing sight is the issue in GCA management.

Authors:  Miguel A González-Gay; Vicente Rodríguez-Valverde
Journal:  Nat Rev Rheumatol       Date:  2010-08       Impact factor: 20.543

4.  Hoarse voice and visual loss.

Authors:  M N Ali; F C Figueiredo
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

Review 5.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Inflammatory and infectious aortic diseases.

Authors:  Amy R Deipolyi; Christopher D Czaplicki; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

Review 7.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  The process from symptom onset to rheumatology clinic in polymyalgia rheumatica.

Authors:  Ediz Dalkılıç; Ayşe Nur Tufan; Emre Hafızoğlu; Merve Hafızoğlu; Fatih Tufan; Ferhat Oksuz; Yavuz Pehlivan; Mustafa Yurtkuran
Journal:  Rheumatol Int       Date:  2014-05-11       Impact factor: 2.631

9.  Clinical approach to optic neuropathies.

Authors:  Raed Behbehani
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Giant cell arteritis (temporal arteritis): A report of four cases from north east India.

Authors:  Judy Laldinpuii; Pratap Sanchetee; Adityendra Lal Borah; Manash Ghose; Nomal Chandra Borah
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.